Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.79B P/E - EPS this Y 72.40% Ern Qtrly Grth -
Income -528.63M Forward P/E -6.62 EPS next Y 197.60% 50D Avg Chg -68.00%
Sales 396.59M PEG -1.19 EPS past 5Y - 200D Avg Chg -63.00%
Dividend N/A Price/Book 8.16 EPS next 5Y 33.30% 52W High Chg -75.00%
Recommedations 1.80 Quick Ratio 2.34 Shares Outstanding 120.58M 52W Low Chg 5.00%
Insider Own 13.22% ROA -41.73% Shares Float 81.04M Beta 0.89
Inst Own 95.98% ROE -290.14% Shares Shorted/Prior 10.67M/10.59M Price 23.96
Gross Margin -4.11% Profit Margin -133.29% Avg. Volume 3,543,182 Target Price 82.13
Oper. Margin -57.74% Earnings Date May 7 Volume 6,490,768 Change -1.07%
About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals, Inc. News
04/23/24 Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
04/04/24 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/01/24 Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
03/28/24 Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
03/19/24 Insider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ...
03/17/24 30 Biggest Biotechnology Companies in the World
03/14/24 Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares
03/11/24 Apellis Pharmaceuticals Inc's Chief Scientific Officer Pascal Deschatelets Sells 69,107 Shares
03/11/24 Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
02/28/24 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript
02/28/24 Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
02/27/24 Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
02/27/24 The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte
02/27/24 Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
02/27/24 Apellis Pharmaceuticals Inc (APLS) Reports Robust Revenue Growth in 2023
02/27/24 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
02/26/24 5 Stocks to Buy That Are Poised to Beat on Earnings This Week
02/26/24 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
02/23/24 Why Apellis (APLS) Might Surprise This Earnings Season
02/20/24 Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know
APLS Chatroom

User Image facecard Posted - 7 minutes ago

$APLS hoping for a recovery here today, 3 decent days of green erased in one day of red

User Image Whiskeyunderthebed Posted - 43 minutes ago

$APLS yesterday alot of funds loaded up-check it out.

User Image OpheliaPaine Posted - 1 hour ago

$APLS Sure -- APLS down 4% because META missed. Makes sense. :-)

User Image JenniFUR2 Posted - 5 hours ago

$APLS APLS fell during the market rally the last month or two…no one wanted in this stock. As traders money maker stocks falter, they look for those beaten up during that time that are moving back up. Enter ALPS. Got 25% more upside to go.

User Image JenniFUR2 Posted - 18 hours ago

$APLS ewww!!! I’ve made enough on a paper for another fur! I’m so excited!!

User Image G101SPM Posted - 20 hours ago

$APLS $49.825 +1.105. DAC (dollar average cost) $46.99 (4.18.24). EXIT $80.00. UPDATE: Announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET.

User Image Tes_t Posted - 21 hours ago

$APLS nice cup and handle pattern

User Image J3DI Posted - 22 hours ago

$APLS strong today....

User Image mcdicedtea Posted - 1 day ago

$APLS there is 50. c'mon Jennifur!!!! Get excited.

User Image Whiskeyunderthebed Posted - 1 day ago

$APLS

User Image Fedex11 Posted - 1 day ago

$APLS looking good on watch for addition to core

User Image JenniFUR2 Posted - 1 day ago

$APLS should bounce up to the $51.50-52 level here quickly....

User Image G101SPM Posted - 1 day ago

@mcdicedtea $APLS is a Legacy Holding --- "All " LH positions in the trading account are working with an net gain of 1725% since March 28th 2023.

User Image facecard Posted - 2 days ago

$APLS wouldn’t be surprised with a close over 50 today, and some upward momentum into the low 50s by eow. Will earnings be great? Who knows, but with the pre-announcement, it’s not worth the risk for shorts to hold over large positions, and they have been seriously playing with this stock over the past 2 weeks.

User Image G101SPM Posted - 2 days ago

$APLS $48.70 bid. DAC $46.99 (4.18.24). EXIT $80.00. NEWS: today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. ^To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website

User Image facecard Posted - 2 days ago

$APLS earnings were last reported Feb 27. The fact that they decided to announce May 7 - usually l a positive to me. However they really need to blow these earnings out of the park, as investor expectations were set high when they claimed Jan and Feb were their highest sales. If they just meet expectations, it won’t be enough to boost the SP out of this slump.

User Image Stock_Titan Posted - 2 days ago

$APLS Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results https://www.stocktitan.net/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-may-7-2024-to-r4pv2990f2oc.html

User Image Georgeson Posted - 2 days ago

$APLS Unusually high AH volume of 143,489. But last trade at $46.20. Don't know how many shares yet but my guess it is a very small number of shares that traded at $46.20.

User Image JenniFUR2 Posted - 2 days ago

$APLS If it were at $70 and base lining like this, I'd sell in a NY minute as that usually signals (to me) a drop coming......since it's already gotten bludgeoned, should move up.

User Image OpheliaPaine Posted - 2 days ago

$APLS Yes -- I think that these schmucks (they know who they are) will realize that there are no more "experts" available to write hit pieces and the stock will move toward its fair value.

User Image Whiskeyunderthebed Posted - 2 days ago

$APLS still stuck in the mud at $47.00- these shorts will start to look and exit soon. Earnings are coming...

User Image stockfoxthejoker Posted - 3 days ago

$APLS Cannot find Syfovre in the CHMP agenda for 22-25th April: https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2024_en.pdf

User Image bluermefox Posted - 5 days ago

$APLS went back and listened again to needham and cowen webcasts, at Cowen they revealed 40k doses distributed by mid feb, so say 34K vials/6k samples, slowdown in March with weather issues et al according to needham conf, 10% less maybe? 31K vials for a total of 65k equates to roughly $135MM syfovre sales for approx 18% increase over Q4, thoughts?

User Image Fedex11 Posted - 5 days ago

$APLS Stocks seems mighty cheap 😎

User Image JenniFUR2 Posted - 5 days ago

$APLS hadn’t looked at the share price since 11 o’clock this morning NASDAQ down 2% I was expecting the worst just looked…couldn’t believe it! Yay!! and friday too! no bummer weekend

User Image Whiskeyunderthebed Posted - 5 days ago

$APLS the $47.00 held, I'm calling this bottom.

User Image camwme Posted - 5 days ago

$APLS this stock gives me a lot of white hair 😂 😂

User Image J3DI Posted - 6 days ago

$APLS FRAUDs at Work

User Image JenniFUR2 Posted - 6 days ago

$APLS and I do like the aggressive hiring in Europe in what was touted as 'for the lauch of SYFRO'

User Image BackwoodsofGeorgia Posted - 6 days ago

$APLS Today we close green

Analyst Ratings
Wedbush Neutral Apr 17, 24
HC Wainwright & Co. Buy Apr 15, 24
Needham Buy Apr 9, 24
Mizuho Neutral Mar 27, 24
JP Morgan Overweight Mar 6, 24
UBS Buy Mar 4, 24
HC Wainwright & Co. Buy Feb 28, 24
Wedbush Neutral Feb 28, 24
Mizuho Neutral Feb 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Watson David O. General Counsel General Counsel Jan 29 Sell 64.1382 906 58,109 104,171 01/31/24
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Jan 29 Sell 64.1382 906 58,109 93,601 01/31/24
Francois Cedric Chief Executive Offi.. Chief Executive Officer Jan 22 Sell 64.996 13,431 872,961 320,467 01/23/24
Watson David O. General Counsel General Counsel Jan 22 Sell 64.996 4,184 271,943 105,077 01/23/24
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Jan 22 Sell 64.996 3,413 221,831 94,507 01/23/24
Sullivan Timothy Eugene Chief Financial Offi.. Chief Financial Officer Jan 22 Sell 64.996 3,551 230,801 95,675 01/23/24
Nicholson Nur Chief Technical Offi.. Chief Technical Officer Jan 22 Sell 64.996 2,593 168,535 68,342 01/23/24
Lewis Karen Chief People Officer Chief People Officer Jan 22 Sell 64.996 1,738 112,963 51,923 01/23/24
Eisele Jeffrey Chief Development Of.. Chief Development Officer Jan 22 Sell 64.996 1,607 104,449 65,836 01/23/24
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jan 22 Sell 64.996 3,913 254,329 1,118,005 01/23/24
DeLong Mark Jeffrey Chief Business & Str.. Chief Business & Strat Officer Jan 22 Sell 64.996 1,384 89,954 65,570 01/23/24
Chopas James George VP/Chief Accounting.. VP/Chief Accounting Officer Jan 22 Sell 64.996 1,061 68,961 39,067 01/23/24
Eisele Jeffrey Chief Development Of.. Chief Development Officer Jan 17 Sell 65.58 5,207 341,475 67,443 01/18/24
Lewis Karen Chief People Officer Chief People Officer Jan 17 Sell 65.58 3,276 214,840 53,661 01/18/24
Eisele Jeffrey Chief Development Of.. Chief Development Officer Jan 16 Sell 66.81 438 29,263 72,650 01/17/24
SCHEIBLER LUKAS Chief Research Offic.. Chief Research Officer Dec 01 Sell 60 10,000 600,000 68,299 12/05/23
SCHEIBLER LUKAS Chief Research Offic.. Chief Research Officer Dec 01 Option 13.85 10,000 138,500 78,299 12/05/23
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Dec 01 Sell 60.9 110,000 6,699,000 76,407 12/05/23
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Dec 01 Option 15.09 110,000 1,659,900 186,407 12/05/23
Francois Cedric Chief Executive Offi.. Chief Executive Officer Nov 21 Sell 48.80 5,000 244,000 269,655 11/21/23
Dunlop A. Sinclair Director Director Nov 17 Sell 49.991 8,894 444,620 122,403 11/21/23
Machiels Alec Director Director Oct 17 Sell 48.5 1,250 60,625 367,420 10/18/23
Machiels Alec Director Director Oct 17 Option 2.67 1,250 3,338 368,670 10/18/23
Machiels Alec Director Director Sep 18 Sell 45 1,250 56,250 367,420 09/19/23
Machiels Alec Director Director Sep 18 Option 2.67 1,250 3,338 368,670 09/19/23
Nicholson Nur Chief Technical Offi.. Chief Technical Officer Sep 18 Sell 44.18 20,350 899,063 53,284 09/19/23
Nicholson Nur Chief Technical Offi.. Chief Technical Officer Sep 18 Option 29.76 9,719 289,237 73,634 09/19/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Sep 08 Sell 42.87 12,000 514,440 1,059,813 09/11/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Sep 08 Option 2.67 18,500 49,395 1,071,813 09/11/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Aug 08 Option 2.67 18,500 49,395 1,065,313 08/09/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Aug 08 Sell 23.66 12,000 283,920 1,053,313 08/09/23
Machiels Alec Director Director Jul 21 Option 2.67 49,779 132,910 367,420 07/24/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jul 10 Sell 84.55 12,000 1,014,600 1,046,813 07/11/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jul 10 Option 2.67 18,500 49,395 1,058,813 07/11/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jun 08 Sell 91.35 12,000 1,096,200 1,040,313 06/09/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jun 08 Option 2.67 18,500 49,395 1,052,313 06/09/23
Sullivan Timothy Eugene Chief Financial Offi.. Chief Financial Officer Jun 05 Sell 89.15 69,779 6,220,798 77,713 06/06/23
Sullivan Timothy Eugene Chief Financial Offi.. Chief Financial Officer Jun 05 Option 10.03 69,779 699,883 147,492 06/06/23
Machiels Alec Director Director May 17 Sell 88.66 1,250 110,825 267,641 05/18/23
Machiels Alec Director Director May 17 Option 2.67 1,250 3,338 268,891 05/18/23
Francois Cedric Chief Executive Offi.. Chief Executive Officer Apr 18 Sell 82.02 30,000 2,460,600 637,601 04/20/23
Francois Cedric Chief Executive Offi.. Chief Executive Officer Apr 18 Option 2.67 50,000 133,500 657,601 04/20/23
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Feb 03 Sell 55.85 5,000 279,250 67,932 02/06/23
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Feb 03 Option 15.09 5,000 75,450 72,932 02/06/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jan 09 Sell 46.08 12,000 552,960 983,780 01/10/23
Deschatelets Pascal Chief Scientific Off.. Chief Scientific Officer Jan 09 Option 2.67 18,500 49,395 995,780 01/10/23
Grossi Federico Chief Medical Office.. Chief Medical Officer Jan 05 Sell 48.79 2,500 121,975 94,884 01/09/23
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 50.7 5,000 253,500 42,907 01/05/23
Townsend Adam J. Chief Commercial Off.. Chief Commercial Officer Jan 03 Option 15.09 5,000 75,450 47,907 01/05/23
Dunlop A. Sinclair Director Director Jan 03 Sell 50.70 500 25,350 132,797 01/05/23